PTGS2 and geroderma osteodysplastica: In patients with GD, statin use for approximately 60 days during a one-year observation period significantly reduced the risk of developing GO, an effect not obtained when patients were treated with cyclooxygenase-2 (COX-2) inhibitors alone (8).